{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-017028","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.635731+00:00","generated_at":"2026-06-15T07:37:22.502705+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vericel reports record Q1 2023 revenue of $41M; MACI up 32%; raises full-year guidance","bullets":["Q1 total revenue $41.0M (+14% YoY); MACI revenue $34.2M (+32% YoY); Epicel $6.8M.","Net loss $7.5M ($0.16/diluted share) vs $7.1M loss a year ago; adjusted EBITDA $1.7M (4% rev).","Full-year 2023 revenue guidance raised to $184-$192M from prior $180-$188M; maintains margin guidance.","Cash and investments $139M, no debt; operating cash flow of $7.9M.","MACI arthroscopic delivery program on track for 2024 commercial launch; NexoBrid P&T approvals ahead of goals."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-017028","json":"https://secwatch.observer/filing/0001628280-23-017028.json","markdown":"https://secwatch.observer/filing/0001628280-23-017028.md","text":"https://secwatch.observer/filing/0001628280-23-017028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000162828023017028/0001628280-23-017028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000162828023017028/vcel-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T07:37:22.502705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}